Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEONASDAQ:APTXNASDAQ:ENLVNASDAQ:GNPXNASDAQ:NBSE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$3.19+0.6%$7.37$2.83▼$9.01$87.25M1.49432,179 shs1.10 million shsAPTXAptinyx$0.10+3.1%$0.08$0.01▼$0.72N/A1.271.32 million shs231,100 shsENLVEnlivex Therapeutics$1.45-3.3%$3.19$1.15▼$4.59$27.85M1.02161,377 shs52,572 shsGNPXGenprex$2.12-4.1%$3.42$2.09▼$42.40$4.05M-0.6171,465 shs8,586 shsNBSENeuBase Therapeutics$0.44+4.7%$0.68$0.39▼$4.80$1.66M0.83202,576 shs25,441 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+0.63%-57.64%-56.66%-31.98%-0.31%APTXAptinyx0.00%0.00%0.00%0.00%-22.33%ENLVEnlivex Therapeutics-3.33%+3.57%-62.92%-47.65%-51.51%GNPXGenprex-4.07%-4.07%-22.63%-77.25%-93.38%NBSENeuBase Therapeutics+4.99%+4.15%-7.69%-29.90%-82.87%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics3.6416 of 5 stars3.51.00.04.51.61.70.6APTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/AENLVEnlivex Therapeutics2.3733 of 5 stars3.53.00.00.01.90.81.3GNPXGenprex4.3001 of 5 stars3.55.00.04.70.60.81.3NBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$36.001,028.53% UpsideAPTXAptinyxN/AN/AN/AN/AENLVEnlivex Therapeutics3.00Buy$7.00382.76% UpsideGNPXGenprex3.00Buy$10.00371.70% UpsideNBSENeuBase TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest GNPX, ENLV, ABEO, APTX, and NBSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$36.004/23/2024ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.004/12/2024ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $7.004/3/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/25/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M24.93N/AN/A$0.60 per share5.32APTXAptinyx$1MN/AN/AN/A$0.57 per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AGNPXGenprexN/AN/AN/AN/A$4.99 per shareN/ANBSENeuBase TherapeuticsN/AN/AN/AN/A$11.04 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)APTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/AENLVEnlivex Therapeutics-$29.07M-$1.56N/AN/AN/AN/A-71.00%-59.08%6/21/2024 (Estimated)GNPXGenprex-$30.86M-$24.80N/AN/AN/AN/A-245.62%-185.50%5/27/2024 (Estimated)NBSENeuBase Therapeutics-$4.37M-$7.70N/A∞N/AN/A-99.74%-60.13%5/9/2024 (Estimated)Latest GNPX, ENLV, ABEO, APTX, and NBSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023ENLVEnlivex TherapeuticsN/A-$0.48-$0.48-$0.48N/AN/A3/18/2024Q4 2023ABEOAbeona Therapeutics-$0.51-$0.64-$0.13-$0.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AAPTXAptinyxN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15APTXAptinyxN/AN/AN/AENLVEnlivex TherapeuticsN/A5.577.34GNPXGenprexN/A2.312.31NBSENeuBase TherapeuticsN/A2.872.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%APTXAptinyxN/AENLVEnlivex Therapeutics1.02%GNPXGenprex14.05%NBSENeuBase Therapeutics12.37%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%APTXAptinyx10.97%ENLVEnlivex Therapeutics12.28%GNPXGenprex11.54%NBSENeuBase Therapeutics13.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableAPTXAptinyx12N/AN/ANot OptionableENLVEnlivex Therapeutics5018.57 million16.29 millionOptionableGNPXGenprex261.91 million1.69 millionOptionableNBSENeuBase Therapeutics373.75 million3.23 millionNot OptionableGNPX, ENLV, ABEO, APTX, and NBSE HeadlinesSourceHeadlineNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from Nasdaqfinanznachrichten.de - April 6 at 8:58 AMNeuBase Therapeutics Announces Receipt of Notice from Nasdaqglobenewswire.com - April 5 at 4:05 PMOnce-promising Pittsburgh biotech firm shutting down for goodtechnical.ly - March 27 at 8:33 PMWhy Neubase Therapeutics (NBSE) Shares Are Nosedivingmsn.com - March 27 at 10:32 AMNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversmsn.com - March 26 at 10:47 AMWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?investorplace.com - March 26 at 9:08 AMNeuBase Therapeutics sets shareholder meeting on dissolution planbizjournals.com - March 25 at 7:44 PMNeuBase Therapeutics Incedition.cnn.com - February 26 at 9:46 AMNeuBase Therapeutics, Inc. (NBSE)finance.yahoo.com - February 20 at 1:40 PMNeuBase Therapeutics Inc (O7P.BE)ca.finance.yahoo.com - January 20 at 12:17 AMMonitoring NeuBase Therapeutics Inc (NBSE) after recent insider movementsknoxdaily.com - January 1 at 2:48 PMCMU halts licensing agreement with NeuBase Therapeuticsbizjournals.com - December 22 at 7:16 PMPsychemedics Corporation Appoints Daniella Mehalik as VP - Financefinance.yahoo.com - November 27 at 10:19 AMNeuBase Therapeutics Inc NBSEmorningstar.com - November 6 at 11:41 PMNeuBase Therapeutics: Other Eventscbonds.com - October 21 at 8:32 AMNeuBase Therapeutics, Inc. (NBSE.MX)finance.yahoo.com - October 6 at 8:56 AMNeuBase Therapeutics Inc. (NBSE) gets rating Reiterated from H.C. Wainwrightknoxdaily.com - September 20 at 6:31 PMMassive Insider Trade At NeuBase Therapeuticsbenzinga.com - September 12 at 3:51 PMNeuBase falls after largest shareholder disposes of part stakemsn.com - September 12 at 3:51 PMNeuBase Therapeutics Issues Statement Regarding Filing By Shareholderfinance.yahoo.com - September 8 at 11:10 AMWhy Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?markets.businessinsider.com - September 6 at 9:07 AMNBSE’s short interest falls to 41130.0 sharesknoxdaily.com - August 25 at 4:34 PMAnalysts Conflicted on These Healthcare Names: NeuBase Therapeutics (NBSE) and Centessa Pharmaceuticals (CNTA)markets.businessinsider.com - August 16 at 7:45 AMNeuBase Therapeutics (NASDAQ: NBSE)fool.com - August 6 at 6:46 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.AptinyxNASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Enlivex TherapeuticsNASDAQ:ENLVEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.GenprexNASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.NeuBase TherapeuticsNASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.